BPC May 31 update

​Iovance IOVA and Turning Point TPTX release updated ASCO data

Price and Volume Movers

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announced updated data from its trial of LN-145 in patients with advanced cervical cancer, which noted an overall response rate (ORR) of 44% and a complete response rate (CR) of 11%. In its trial of LN-144 (lifileucel) in patients with melanoma, the second cohort demonstrated an ORR of 38% (2 complete responses and 23 partial responses). The treatments use a type of Tumor Infiltrating Lymphocyte (TIL) therapy, which involves removing immune cells from the tumor, growing them in the lab before infusing the cultured cells back into the patient. Shares closed down 8% to $16.35.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) announced updated interim data from its ongoing Phase 1/2 TRIDENT-1 trial of repotrectinib in ROS1-positive non-small cell lung cancer (NSCLC) patients. In tyrosine kinase inhibitor (TKI) naïve patients, the overall response rate (ORR) was 82% (9/11). However, four total Grade 5 TEAEs (treatment-related adverse events) were noted with one of the four determined to be possibly treatment related. Shares closed down 10% to $34.82.

Genocea Biosciences, Inc. (NASDAQ: GNCA) closed up 25% to $5.61. Shares of the micro-cap company attracted attention following a press release where it noted its upcoming ASCO presentation of GEN-009 tomorrow was noted in the Journal of Clinical Oncology as a top 10 featured abstract in immuno-oncology.

Hemispherx Biopharma, Inc. (NYSE American: HEB) announced a 1-for-44 reverse stock split will be effective on June 10, 2019, and begin trading on a split-adjusted basis on June 11, 2019. Shares closed down 11% to $0.10.

ContraVir Pharmaceuticals, Inc. (Nasdaq: CTRV) also announced a 1-for-70 reverse split. Shares will begin trading on a split-adjusted basis on June 3, 2019. Shares closed down 11% to $0.11.

CytRx Corporation (NASDAQ: CYTR) announced that it will delist from Nasdaq to the OTCQB Venture Market on June 4, 2019. Shares closed down 26% to $0.38.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) saw its shares close up 141% to $4.08. Shares of the nano-cap company (market cap $11m) rose following the data noted in a SEC filing from its ongoing first line trial in patients with MGMT-unmethylated glioblastoma multiforme (GBM). The company noted:

For the fifteen patients who have received at least one assessment, eight patients were assessed with a best response of “Complete Response” (8/15, 53.3% CR) and seven patients were assessed with a best response of “Stable Disease” (7/15, 46.7% SD)."

-

Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume

ADVANCERS:

Ocular Therapeutix, Inc. (OCUL): $2.90; +18%.

GTx, Inc. (GTXI): $1.18; +12%.

Hoth Therapeutics, Inc. (HOTH): $6.50; +12%.

Trevi Therapeutics, Inc. (TRVI): $9.99; +10%.

Myovant Sciences Ltd. (MYOV): $9.83; +9%.

DECLINERS:

XBiotech Inc. (XBIT): $7.20; -21%.

Inovio Pharmaceuticals, Inc. (INO): $2.39; -15%.

MediciNova, Inc. (MNOV): $9.92; -13%.

Adial Pharmaceuticals, Inc. (ADIL): $1.85; -11%.

Armata Pharmaceuticals, Inc. (ARMP): $3.19; -11%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ALNY – Alnylam Pharmaceuticals Inc.
ALN-AGT
Hypertension

Phase 1 Phase 1 dosing has commenced - noted May 31, 2019. Initial data due late-2019.
$7.6 billion

IOVA – Iovance Biotherapeutics Inc.
LN-144 - lifileucel
Refractory metastatic melanoma

BLA Filing Phase 2 updated data noted ORR 38 percent (2 CRS; 23 PRs). BLA filing due 2H 2020.
$2.7 billion

IOVA – Iovance Biotherapeutics Inc.
LN-145
Cervical cancer

Phase 2 Phase 2 data released May 31, 2019 noted ORR 44%; CR 11%.
$2.7 billion

TPTX – Turning Point Therapeutics Inc.
Repotrectinib (TPX-0005) - TRIDENT-1
Non-small-cell lung cancer (NSCLC) and solid tumors

Phase 1/2 Phase 2 trial initiation announced June 20, 2019 with interim data due 2H 2020.
$1.3 billion